In the face of the emerging variants of SARS-CoV-2, there is an urgent need to develop a vaccine that can induce fast, effective, long-lasting and broad protective immunity against SARS-CoV-2. Here, we developed a trimeric SARS-CoV-2 S protein vaccine candidate adjuvanted by PIKA, which can induce robust cellular and humoral immune responses. The results showed a high level of neutralizing antibodies induced by the vaccine was maintained for at least 400 days. In the study of non-human primates, PIKA adjuvanted S-trimer induced high SARS-CoV-2 neutralization titers and protected from virus replication in the lung following SARS-CoV-2 challenge. In addition, the long-term neutralizing antibody response induced by S-trimer vaccine adjuvanted by PIKA could neutralize multiple SARS-CoV-2 variants and there is no obvious different among the SARS- CoV-2 variants of interest or concern, including B.1.351, B.1.1.7, P.1, B.1.617.1 and B.1.617.2 variants. These data support the utility of S-trimer protein adjuvanted by PIKA as a potential vaccine candidate against SARS-CoV-2 infection. Supplementary Information The online version contains supplementary material available at 10.1186/s43556-021-00054-z.
【저자키워드】 COVID-19, SARS-CoV-2, Vaccine, variants, S-trimer, PIKA, 【초록키워드】 neutralizing antibody, B.1.351, SARS-COV-2 infection, SARS-CoV-2 variant, B.1.617.2, lung, Protein, protective immunity, B.1.1.7, non-human primates, P.1, B.1.617.1, SARS- CoV-2, vaccine candidate, variants of interest, virus replication, utility, humoral immune responses, Neutralizing antibody response, SARS-CoV-2 neutralization, SARS-CoV-2 S protein, cellular, Support, supplementary material, variants of SARS-CoV-2, effective, neutralize, trimeric, robust, develop, addition, long-lasting, induce, the vaccine, 【제목키워드】 COVID-19 vaccine, immune response, long-lasting,